Opentrons hires Gautam Prabhu as chief technology officer to accelerate development of robotic engineering solutions for automated laboratories

Mr. Prabhu will lead the company’s data science and engineering teams to accelerate the development of automated laboratory robotics products

Brooklyn, NY – July 18, 2023 – Opentrons Labworks, Inc., a leader in laboratory automation and manufacturer of accessible laboratory robots, today announced the appointment of Gautam Prabhu as Chief Technology Officer. Mr. Prabhu, who has more than two decades of experience leading software engineering organizations, is poised to play a key role in the expansion of the company's Opentrons robotics and neochromosome business units. As CTO, Mr. Prabhu will accelerate the product development of Opentrons’ data science and engineering teams and ensure the successful implementation of the company’s roadmap. He will also serve as the company's representative in technology-focused discussions with the board of directors and investors.

"Gautam's expertise in building advanced enterprise SaaS solutions, launching product lines and expanding engineering capabilities is a perfect fit with our mission," said Jonathan Brennan-Badal, CEO of Opentrons. "We are excited to welcome him to our team. Especially during this exciting growth phase following the successful launch of the Flex robot in May."

Mr. Prahbhu brings a wealth of experience to Opentrons, including leadership roles of increasing responsibility at PagerDuty and Zendesk. At PagerDuty, he most recently served as director of engineering, overseeing product lines, infrastructure, shared services and data science, while also leading significant team growth and driving major software initiatives. Prior to joining PagerDuty, he served as Vice President of Engineering at Zendesk, where he played a critical role in managing shared services and building software-as-a-service productivity applications used by hundreds of thousands of enterprises. Additionally, Mr. Prabhu serves as an advisor to Y Combinator Continuity, further solidifying his expertise in the technology industry.

“The technology teams at Opentrons Robotics and Neochromosome are pushing the boundaries of automation and engineering in the life sciences industry,” said Mr. Prabhu. "I look forward to helping the company usher in a new era of laboratory solutions that enable researchers to make groundbreaking discoveries. Additionally, I am excited to bring my engineering expertise to the field of robotics and my passion for advancing science Bringing the world of robotics to unlock the full potential of laboratory automation.”

About Opentrons

Opentrons Labworks, Inc. is a disruptive life sciences company and current leader in the entry-level laboratory automation market, accelerating innovation in research and healthcare through its integrated laboratory platform, including the Opentrons Robotics and Neochromosome business units. Opentrons has raised more than $200 million in funding and achieved unicorn status with its first- and second-generation robots, OT-One and OT-2. Opentrons Robotics provides flexible, easy-to-use laboratory robots to thousands of institutions, automating R&D operations and making robotics a vast open source library accessible to life science researchers worldwide. Opentrons are used in thousands of academic, biopharmaceutical, synthetic biology and clinical research laboratories in more than 40 countries by institutions such as the Mayo Clinic, Stanford University, Harvard University and MIT. For more information, please visit https://opentronslabworks.com/.

About Neochromosome, Inc.

Neochromosome is a biotechnology company with a disruptive longDNA™ platform that is changing the world of bioengineering. Rather than making piecemeal edits to existing genomes, Neochromosomes focus on de novo design and construction of multigene pathways, chromosomes, or even entire genomes for precise delivery in eukaryotic cells. Headquartered in New York City, Neochromosome is a wholly owned subsidiary of Opentrons Labworks. For more information, visit https://neochromosome.com.